chartexchange

Metagenomi Therapeutics Announces FDA Clearance of Investigational New Drug Application for MGX-001 and Reports Third Quarter 2026 Financial Results

GlobeNewswire Inc. | Nov 10, 2026 4:05 PM EST

FDA clearance enables initiation of a first-in-human Phase 1/2 trial of MGX-001 in patients with hemophilia A

Read original article